证券代码：688513 证券简称：苑东生物 公告编号：2025-072 成都苑东生物制药股份有限公司 关于选举第四届董事会职工代表董事的公告 2025 年 10 月 10 日 1 附件：职工代表董事简介 伯小芹：女，1982 年 4 月生，中国国籍，中共党员，无境外永久居留权， 本科学历，会计学学士学位，中级会计师。2010 年 6 月至 2012 年 7 月先后任公 司成本会计/会计主管；2012 年 7 月至 2017 年 4 月任四川阳光润禾药业有限公司 财务经理；2017 年 4 月至 2017 年 10 月任销售财务副总监；2017 年 10 月至今任 公司总会计师，2022 年 10 月至今任公司财务总监，2024 年 12 月 27 日当选为公 司第四届董事会非独立董事。曾就职于江苏延申生物科技股份有限公司。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 成都苑东生物制药股份有限公司（以下称"公司"）于 2025 年 10 月 9 日召开 的 2025 年第二次临时股东大会审议通过了《关于取消监事会、修订< ...

证券代码：688513 证券简称：苑东生物 公告编号：2025-071 成都苑东生物制药股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 10 月 9 日 （二） 股东大会召开的地点：四川省成都市双流区安康路 8 号，苑东生物 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： 1、 公司在任董事9人，出席9人； 2、 公司在任监事3人，出席3人； 3、 公司董事会秘书现场出席本次会议；公司其他高级管理人员列席本次会议。 二、 议案审议情况 （一） 非累积投票议案 | 1、出席会议的股东和代理人人数 | 41 | | --- | --- | | 普通股股东人数 | 41 | | 2、出席会议的股东所持有的表决权数量 | 90,285,615 | | 普通股股东所持有表决权数量 | 90,285,615 | | 3、出席 ...

法律意见书 植德京(会)字[2025]0139 号 二〇二五年十月 北京市东城区东直门南大街 1 号来福士中心办公楼 12 层 邮编：100007 12th Floor, Raffles City Beijing Office Tower, No.1 Dongzhimen South Street, Dongcheng District, Beijing 100007 P.R.C 电话(Tel)：010-56500900 传真(Fax)：010-56500999 www.meritsandtree.com 北京植德律师事务所 关于成都苑东生物制药股份有限公司 2025 年第二次临时股东大会的 北京植德律师事务所 关于成都苑东生物制药股份有限公司 2025 年第二次临时股东大会的 法律意见书 植德京(会)字[2025]0139 号 致：成都苑东生物制药股份有限公司（贵公司） 北京植德律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出 席并见证贵公司 2025 年第二次临时股东大会（以下简称"本次会议"）。 本所律师参加本次会议进行见证，并根据《中华人民共和国公司法》（以下 简称"《公司法》"）、《中华人 ...

Core Viewpoint - Yuan Dong Bio is focusing on innovation-driven development in the biopharmaceutical sector, with a comprehensive industrial layout in chemical raw materials, high-end chemical drugs, and biological drugs [1] Summary by Relevant Sections Innovation Drug Development - The company has over 80 ongoing research projects, with innovative drug projects accounting for 24.4% of the total, including small molecule new drugs, biological drugs, and modified new drugs [1] - In the small molecule new drug category, the drug "Yoglitin Tablets" has achieved the expected goals in its Phase III clinical trial, while EP-0108 capsules, EP-0146 tablets, and EP-0186 tablets have received clinical trial approvals [1] - In the biological drug sector, the anesthetic and analgesic drug EP-9001A monoclonal antibody has completed Phase Ib clinical trials, and the ADC innovative drug YLSH003 has submitted an IND and received clinical approval [1] - Several modified new drugs, such as oral solution of chloral hydrate and extended-release oxycodone tablets, have been submitted for production, with multiple distinctive modified new drugs entering clinical stages [1] Strategic Investments and Collaborations - The company is actively tracking global cutting-edge technologies and accelerating its innovation transformation through strategic investments, external introductions, and collaborative development [1] - Following the acquisition of shares in Shanghai Chaoyang, the company's indirect shareholding increased from 11.36% to 30.68%, and it plans to further increase its stake to achieve controlling interest, raising its indirect ownership to 51.48% [1] - This strategic control over Shanghai Chaoyang will enhance the company's pipeline in frontier technology areas such as molecular glue, PROTAC (proteolysis-targeting chimeras), and DAC (drug-antibody conjugates), strengthening its R&D capabilities in innovative drugs [1]

Core Viewpoint - Chengdu Yuandong Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the registration of its drug, Ethyl Pheylbutazone Tablets, marking a significant milestone for the company in the pharmaceutical market [1][2]. Drug Basic Information - Drug Name: Ethyl Pheylbutazone Tablets - Dosage Form: Tablets - Specification: 50mg - Registration Category: Chemical Drug Class 4 - Validity Period: 18 months - Holder of Marketing Authorization: Chengdu Shode Pharmaceutical Co., Ltd. - Production Company: Chengdu Shode Pharmaceutical Co., Ltd. - Registration Standard Number: YBH23792025 - Acceptance Number: CYHS2402415 - Certificate Number: 2025S02973 - Approval Document Number: Guoyao Zhunzi H20255554 - Approval Conclusion: The drug meets the registration requirements as per the relevant laws and regulations [1]. Drug Indications and Market Context - The primary active ingredient is Ethyl Pheylbutazone, indicated for conditions such as cervical, shoulder, and lumbar pain, as well as various spastic paralysis conditions [2]. - The drug was originally developed by Eisai Co., Ltd. in Japan and was first approved for sale in Japan in February 1983, later imported to China in July 2004 [2]. - It is classified as a Category B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Directory (2024) [2]. - The drug is the first generic drug approved under the new registration classification, equivalent to passing the consistency evaluation [2]. - Sales data from major public hospitals indicate that the expected sales for Ethyl Pheylbutazone Tablets in 2024 are approximately 102.61 million yuan, reflecting a year-on-year growth of 14.01% [2]. Impact on the Company - The approval of Ethyl Pheylbutazone Tablets signifies that the product meets the necessary registration requirements, although it is not expected to have a significant impact on the company's short-term performance [3]. - The period from approval to market production may face uncertainties, and the company will fulfill its information disclosure obligations as required by law [3].

Core Viewpoint - Chengdu Yuandong Pharmaceutical Co., Ltd. has received the drug registration certificate for its product, Hydrochloride Ephedrine Tablets, marking a significant milestone in its product portfolio and compliance with regulatory standards [1][2]. Drug Basic Information - Drug Name: Hydrochloride Ephedrine Tablets - Dosage Form: Tablets - Specification: 50mg - Registration Category: Class 4 Chemical Drug - Validity Period: 18 months - Holder of Marketing Authorization: Chengdu Shuo De Pharmaceutical Co., Ltd. - Production Company: Chengdu Shuo De Pharmaceutical Co., Ltd. - Drug Registration Standard Number: YBH23792025 - Approval Conclusion: The product meets the requirements for drug registration and has been granted a registration certificate [1][2]. Drug Indications - Hydrochloride Ephedrine Tablets are indicated for: 1. Improving muscle tension in conditions such as cervical shoulder-arm syndrome, periarthritis of the shoulder, and low back pain 2. Spastic paralysis caused by cerebrovascular disorders, spastic myelopathy, cervical spondylosis, postoperative sequelae, traumatic sequelae, amyotrophic lateral sclerosis, infantile cerebral palsy, and other spinal cord diseases [2]. Market Performance - The sales amount for Hydrochloride Ephedrine Tablets in public hospitals in key provinces and cities is projected to be approximately 102.61 million yuan in 2024, reflecting a year-on-year growth of 14.01% [3]. Impact on the Company - The approval of Hydrochloride Ephedrine Tablets signifies that the product meets the necessary registration requirements and is considered to have passed the consistency evaluation. However, it is noted that the approval will not have a significant impact on the company's short-term performance [4].

Core Viewpoint - The company Yuandong Biotech (688513.SH) announced that its wholly-owned subsidiary Chengdu Shode Pharmaceutical Co., Ltd. has received the drug registration certificate from the National Medical Products Administration for its product, Etifoxine Hydrochloride Tablets [1] Group 1: Product Information - The drug Etifoxine Hydrochloride Tablets is primarily indicated for improving muscle tension states associated with conditions such as cervical shoulder-arm syndrome, periarthritis of the shoulder, and low back pain [1] - Additional indications include treatment for spastic paralysis caused by cerebrovascular disorders, spastic myelopathy, cervical spondylosis, postoperative sequelae (including brain and spinal cord tumors), and post-traumatic sequelae (such as spinal cord injury and head trauma) [1] - The drug is also indicated for conditions like amyotrophic lateral sclerosis, infantile cerebral palsy, spinocerebellar degeneration, spinal vascular disorders, subacute optic neuritis myelitis (SMON), and other brain and spinal cord diseases that lead to spastic paralysis [1]

Core Viewpoint - Company Yuandong Biotech (688513.SH) has received approval from the National Medical Products Administration for its drug, Ephedrine Hydrochloride Tablets, which is expected to address various medical conditions related to muscle tension and spastic paralysis [1] Group 1: Drug Approval - The company's wholly-owned subsidiary, Chengdu Shode Pharmaceutical Co., Ltd., has been granted a Drug Registration Certificate for Ephedrine Hydrochloride Tablets [1] - The approval signifies a significant milestone for the company in expanding its pharmaceutical portfolio [1] Group 2: Indications and Uses - Ephedrine Hydrochloride Tablets are indicated for improving conditions such as cervical shoulder-arm syndrome, periarthritis of the shoulder, and low back pain related to muscle tension [1] - The drug is also applicable for various neurological and muscular disorders, including cerebrovascular disorders, spastic myelopathy, cervical spondylosis, and post-surgical sequelae [1]

Core Viewpoint - Yuan Dong Biotech (688513) announced the approval of its subsidiary Chengdu Shuo De Pharmaceutical's drug registration certificate for Ephedrine Hydrochloride Tablets by the National Medical Products Administration [1] Group 1 - The active ingredient of Ephedrine Hydrochloride Tablets is Ephedrine Hydrochloride [1] - The primary indications for the drug include improvement of muscle tension conditions related to cervical shoulder-arm syndrome, periarthritis of the shoulder, low back pain, cerebrovascular disorders, spastic myelopathy, cervical spondylosis, and postoperative sequelae [1]

Core Viewpoint - Yuan Dong Biotech (688513.SH) announced that its wholly-owned subsidiary Chengdu Shuo De Pharmaceutical Co., Ltd. has received the Drug Registration Certificate approved by the National Medical Products Administration for its product, Ephedrine Hydrochloride Tablets [1] Group 1: Company Developments - Chengdu Shuo De Pharmaceutical has been granted approval for Ephedrine Hydrochloride Tablets, which is a significant milestone for the company [1] - The active ingredient of the tablets is Ephedrine Hydrochloride, indicating the company's focus on addressing various medical conditions [1] Group 2: Product Indications - The primary indications for Ephedrine Hydrochloride Tablets include improving muscle tension states in conditions such as cervical shoulder-arm syndrome, periarthritis of the shoulder, and low back pain [1] - The product is also indicated for spastic paralysis caused by cerebrovascular disorders, spastic myelitis, cervical spondylosis, postoperative sequelae, and other neurological conditions [1]